Key clinical point: For many patients with hemophilia A, with or without inhibitors, monthly treatment with emicizumab is enough to ensure a high level of bleed control.
Major finding: Twenty-three out of 41 patients (56.1%) reported no treated bleeds.
Study details: An ongoing, open-label phase 3 trial involving patients aged 12 years and older with severe congenital hemophilia A or hemophilia A with FVIII inhibitors who were receiving treatment with bypassing agents or FVIII concentrates.
Disclosures: F. Hoffman-La Roche and Chugai funded the study. The investigators reported financial relationships with the study sponsors and other companies.
Pipe SW et al. Lancet Haem. 2019 Apr 16. doi: 10.1016/S2352-3026(19)30054-7.